ADAR1's Private Funds Hold 6% Of Enanta As Hepatitis C Royalties Decline

The adviser and its sole manager reported the same shares, while Enanta expects its cash to fund operations into fiscal 2029.

Share
ADAR1's Private Funds Hold 6% Of Enanta As Hepatitis C Royalties Decline

Private funds managed by ADAR1 Capital Management hold a 6% stake in Enanta Pharmaceuticals, which develops small-molecule drugs for virology and immunology. The investment adviser reported the position as of September 30 in a passive ownership disclosure filed Monday, while Enanta's hepatitis C royalty revenue has declined.

One Holding, Shared Voting Power

The position comprises 1,733,320 common shares directly owned by ADAR1's private investment funds. ADAR1 reported indirect beneficial ownership, meaning the shares are held through the funds it manages.

Daniel Schneeberger, ADAR1's sole manager, reported the same 1,733,320 shares and 6% interest. Both reporting persons have shared voting authority over that holding; the two entries describe the same fund-owned shares.

ADAR1 and Schneeberger certified that they bought and hold the securities in ordinary business without a purpose of changing or influencing Enanta's control. The reported percentage uses a base of 29,125,402 outstanding shares as of August 7, 2026.

Hepatitis C Revenue Falls

Enanta reported fiscal fourth-quarter revenue of $12.9 million, down from $15.1 million a year earlier, in its results announcement. All of that revenue came from worldwide sales of AbbVie's MAVYRET/MAVIRET hepatitis C treatment.

Enanta discovered glecaprevir, the antiviral AbbVie sells as part of that combination. Substantially all of Enanta's royalty revenue since August 2017 has come from the regimen, sold as MAVYRET in the U.S. and MAVIRET elsewhere across more than 50 countries.

Enanta recorded a full-year loss of $68.2 million on revenue of $63 million.

Cash Supports The RSV Pipeline

Enanta held $194.5 million in cash and marketable securities at September 30. Management expects that money to support operations into fiscal 2029.

The company's own pipeline includes two clinical-stage candidates for respiratory syncytial virus, or RSV. It is also developing early-stage oral drugs for type 2 inflammatory diseases, including chronic spontaneous urticaria and atopic dermatitis.

Enanta expects results from its mid-stage pediatric trial of the RSV drug zelicapavir in the first quarter of 2027.

Sources

More on Enanta Pharmaceuticals

All Enanta Pharmaceuticals (ENTA) coverage →